QuantumDx
CARB-X Awards SpeeDx up to $3.7 Million for CT/NG Test on QuantumDx Q-POC
SpeeDx will develop a rapid, portable test for chlamydia and gonorrhea that can determine the latter's antimicrobial susceptibility, as well.
QuantuMDx Raises $15.1M to Support Scale Up of Point-of-Care Molecular Diagnostic System
The firm's CEO said that its MDx system is available for research use and going through CE-IVD marking ahead of its full commercial launch.
QuantuMDx Receives CE-IVD Marking for SARS-CoV-2 Test
The company said it has scaled up production capacity to two million reactions per week and has the potential to scale up to three million reactions per week.
A handful of rapid 2019-nCoV assays are in the works which could help triage patients more effectively and avoid unnecessary quarantines.
QuantuMDx Raises $14M to Support Development of POC Genotyping Assay
The company said it has started the CE mark approval process of commissioned high-risk HPV genotyping assays and expects to certify them this year.
Dec 10, 2019
Ontera, QuantuMDx Partner on Sepsis Test Development
Jan 24, 2018
QuantuMDx Raises $12M
Nov 28, 2016
Oct 28, 2014
Jan 8, 2014
Jan 8, 2014
Jan 7, 2014